The impact of JAK2 allele burden on the efficacy of JAK inhibitors in myelofibrosis скачать в хорошем качестве

The impact of JAK2 allele burden on the efficacy of JAK inhibitors in myelofibrosis

Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the varying efficacy of JAK inhibitors in patients with myelofibrosis (MF) who have either cytopenic or proliferative disease. Ruxolitinib and fedratinib show greater effectiveness in patients with proliferative disease, characterized by preserved blood counts and a higher JAK2 allele burden. In contrast, momelotinib and pacritinib are more effective for those with cytopenic disease, who generally have less favorable outcomes. Dr Bose highlights that these differences are primarily based on clinical phenotype rather than JAK2 allele burden. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.